Table 2. The clinical characteristics of patients in different cohorts.
| Clinical characteristics | Entire TCGA CRC samples (n=573) | First internal validation cohort (n=288) | Second internal validation cohort (n=285) | P-overall |
|---|---|---|---|---|
| Age, mean (SD) | 65.5 (12.4) | 64.6 (12.2) | 66.5 (12.5) | 0.168 |
| Gender (%) | 0.814 | |||
| Female | 259 (45.2) | 134 (46.5) | 125 (43.9) | |
| Male | 314 (54.8) | 154 (53.5) | 160 (56.1) | |
| Stage (%) | 0.153 | |||
| Stage I + II | 303 (52.9) | 137 (47.6) | 166 (58.2) | |
| Stage III + IV | 250 (43.6) | 139 (48.3) | 111 (38.9) | |
| Unknown | 20 (3.5) | 12 (4.2) | 8 (2.8) | |
| T (%) | 0.779 | |||
| T1 + 2 | 118 (20.6) | 64 (22.2) | 54 (18.9) | |
| T3 + 4 | 453 (79.1) | 222 (77.1) | 231 (81.1) | |
| Tis | 1 (0.2) | 1 (0.3) | 0 | |
| Unknown | 1 (0.2) | 1 (0.3) | 0 | |
| M (%) | 0.302 | |||
| M0 | 426 (74.3) | 208 (72.2) | 218 (76.5) | |
| M1 | 82 (14.3) | 39 (13.5) | 43 (15.1) | |
| MX_unknown | 65 (11.3) | 41 (14.2) | 24 (8.4) | |
| N (%) | 0.052 | |||
| N0 | 322 (56.2) | 146 (50.7) | 176 (61.8) | |
| N1 + 2 | 248 (43.3) | 139 (48.3) | 109 (38.2) | |
| NX_unknown | 3 (0.5) | 3 (1.0) | 0 |
T, tumor; M, metastasis; N, lymph node; P-overall, the P value is indicated for the chi-square test and Kruskal-Wallis test among the three groups, significant threshold <0.05; CRC, colorectal cancer.